New drug hope for Tough-to-Treat throat cancer
NCT ID NCT06118333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 participants will be randomly assigned to receive either the new drug or a standard chemo chosen by their doctor. The main goals are to see if the new drug shrinks tumors and helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV)
What this could lead to
If it works, this could offer a new treatment option for people with advanced nasopharyngeal cancer who have run out of standard therapies.
What could go wrong
This is a late-stage trial, but the drug is still experimental. It may not work better than existing chemo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China